5-HT2C Receptors in the Pathophysiology of CNS Disease

1. Front Matter

   Pages i-xi

   PDF

2. The Making of the 5-HT2C Receptor

   • Jose M. Palacios, Angel Pazos, Daniel Hoyer

   Pages 1-16

3. Serotonin 5-HT2C Receptors: Chemical Neuronatomy in the Mammalian Brain

   • Guadalupe Mengod

   Pages 17-27

4. The Medicinal Chemistry of 5-HT2C Receptor Ligands

   • Marcello Leopoldo, Enza Lacivita, Paola De Giorgio, Francesco Berardi, Roberto Perrone

   Pages 29-50

5. Insights into 5-HT2C Receptor Function Gained from Transgenic Mouse Models

   • Stephen J. Bonasera

   Pages 51-73

6. Serotonin 5-HT2C Receptor Signal Transduction

   • Maria N. Garnovskaya, John R. Raymond

   Pages 75-96

7. Homology Modeling of 5-HT2C Receptors

   • Nicolas Renault, Amaury Farce, Philippe Chavatte

   Pages 97-127

8. 5-HT2C Receptor Dimerization

   • Katharine Herrick-Davis, Dinah T. Farrington

   Pages 129-155

9. RNA Editing of 5-HT2C Receptor and Neuropsychiatric Diseases

   • Kazuya Iwamoto, Miki Bundo, Tadafumi Kato

   Pages 157-167

10. Serotonergic Control of Adult Neurogenesis: Focus on 5-HT2C Receptors

    • Annie Daszuta

    Pages 169-185

11. The Constitutive Activity of 5-HT2C Receptors as an Additional Modality of Interaction of the Serotonergic System

    • Sylvia Navailles, Philippe De Deurwaerdère

    Pages 187-213

12. The 5-HT2C Receptor Subtype Controls Central Dopaminergic Systems: Evidence from Electrophysiological and Neurochemical Studies

    • Giuseppe Di Giovanni, Ennio Esposito, Vincenzo Di Matteo

    Pages 215-247

13. The Role of 5-HT2C Receptors in the Pathophysiology and Treatment of Depression

    • Eliyahu Dremencov, Joost H. A. Folgering, Sandra Hogg, Laurence Tecott, Thomas I. F. H. Cremers

    Pages 249-260

14. 5-HT2C Receptors and Suicidal Behavior

    • Fabio Panariello, Naima Javaid, Vincenzo De Luca

    Pages 261-274

15. The 5-HT2C Receptor as a Target for Schizophrenia

    • Herbert Y. Meltzer, Liwen Sun, Hitoshi Hashimoto

    Pages 275-291

16. Serotonin and Reward-Related Behavior: Focus on 5-HT2C Receptors

    • Paul J. Fletcher, Guy A. Higgins

    Pages 293-324

17. Tat-3L4F: A Novel Peptide for Treating Drug Addiction by Disrupting Interaction Between PTEN and 5-HT2C Receptor

    • Amy Hu, Lintao Jia, Jean-Christian Maillet, Xia Zhang

    Pages 325-337

18. The Role of Serotonin in Eating Behavior: Focus on 5-HT2C Receptors

    • Jason C. G. Halford

    Pages 339-350

19. Physiological and Pathophysiological Aspects of 5-HT2c Receptors in Basal Ganglia

    • Philippe De Deurwaerdère, Laurence Mignon, Marie-Françoise Chesselet

    Pages 351-382

20. Modeling Tardive Dyskinesia: Predictive 5-HT2C Receptor Antagonist Treatment

    • Richard M. Kostrzewa

    Pages 383-392

Part of Springer’s “The Receptors,” series, this text is the first ever overview on the research of 5-HT2c receptors. 5-HT2c receptor research has been productive for twenty-five years, but recent years have seen an extraordinary increase in both amount produced and insight gained. 5-HT2c is a prominent central serotonin receptor subtype widely expressed within the central and the peripheral nervous system and is thought to play a key role in the regulation of numerous behaviors. This text covers the molecular, cellular, anatomical, biochemical and behavioral aspects of this receptor, highlighting its distinctive regulatory properties and the emerging functional significance of constitutive activity and RNA-editing in vivo. It also investigates the receptors’ therapeutic potential in many diseases, treated individually in separate chapters, including depression, drug abuse, schizophrenia, eating disorders, Parkinson’s disease, Prader-Willi Syndrome, Alzheimer’s disease and epilepsy.

From the reviews:

“The book is well presented with good use of diagrams … . There is a good mix of international authors with acknowledged leaders in the field being responsible for some key chapters. … In summary this is a useful book describing the properties of a receptor that may well turn out to be a therapeutically important drug target with selective ligands already being evaluated in phase II trials for control of appetite.” (R. G. Hill, British Journal of Clinical Pharmacology, May, 2011)

• , Department of Physiology and Biochemistr, University of Malta, Malta, Italy

  Giuseppe Di Giovanni

• Centro di Ricerche Farmacologiche e, Biomediche, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy

  Ennio Esposito, Vincenzo Di Matteo

Policies and ethics